Ecopharmacovigilance is a crucial aspect of pharmacology that delves into the environmental impact of pharmaceutical substances, specifically focusing on their pharmacodynamics. Pharmacodynamics involves the study of how drugs interact with the body and the subsequent biological responses. In the context of ecopharmacovigilance, it extends beyond human health to assess the effects of pharmaceuticals on ecosystems and wildlife. Understanding the pharmacodynamics of drugs in the environment is vital for evaluating potential ecological risks. It encompasses the examination of how drugs persist, transform, and exert their effects in various environmental compartments. This field explores the intricate interplay between pharmaceuticals and non-target organisms, assessing both short-term and long-term impacts on biodiversity and ecosystem functioning. By scrutinizing pharmacodynamic aspects, ecopharmacovigilance aims to identify potential hazards posed by pharmaceutical residues in the environment and develop strategies to mitigate adverse effects. This involves comprehensive research to comprehend the fate of drugs in environmental matrices, their bioaccumulation, and potential consequences for ecosystems. Ultimately, integrating pharmacodynamics into ecopharmacovigilance practices ensures a holistic approach to pharmaceutical safety, addressing concerns beyond human health to safeguard the delicate balance of our ecosystems.
Title : Ectopically expressed olfactory receptors as an untapped family of drug targets and discovery of agonists and antagonists of OR51E1, an understudied G protein-coupled receptor
Vladlen Slepak, University of Miami Miller School of Medicine, United States
Title : Managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Analytical strategies for solid-state forms in drug development
Maria Cristina Gamberini, University of Modena e Reggio Emilia, Italy
Title : Understanding drug transport in plasma: The role of protein binding
Saad Tayyab, UCSI University, Malaysia
Title : Innovative development and delivery of biologics for chronic obstructive pulmonary disease
Yong Xiao Wang, Albany Medical College, United States
Title : Search for novel biomarkers and therapeutic targets for inflammatory disease
Madhav Bhatia, University of Otago, New Zealand
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model through de-sign-inspired biotech- & biopharma-driven applications and upgraded business mar-keting to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences & InMedStar, Russian Federation
Title : Design and evaluation of exo-itc: A bilayer fibrous system for controlled exosome delivery in dermatological applications
Luis Jesus Villarreal Gomez, FCITEC - Universidad AutĂłnoma de Baja California, Mexico
Title : Abuse-deterrent dosage form technique utilizing a fusion of innovative pharmaceuticals and ion exchange resin
Bhupendra Gopalbhai Prajapati, Parul University, India
Title : Macitentan/tadalafil combination– An additional value in pharmacotherapy of pulmonary arterial hypertension
Miroslav Radenkovic, University of Belgrade, Serbia